Ionis Pharmaceuticals is to work with Bicycle Therapeutics to open up new avenues for its oligonucleotide platform using novel drug delivery technologies to target muscle tissue, the heart and the brain.
The company is paying $45m upfront to Bicycle, as well as development, commercial milestones and royalties, in exchange for access...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)


